Champions Oncology price to free cash flow CSBR

Market value divided by free cash flow over the last twelve months, since 2018.

Today, Oct 23, 2026: n/m; not a meaningful number
Last meaningful: 22.3×; Jul 2026
8-year median: 30.9×
8-year range: 9.4× to 485×
Peer median: 11.8×

Champions Oncology's price to free cash flow is not a meaningful number today: free cash flow over the last twelve months was zero, negative or not reported.

It was last meaningful in Jul 2026, at 22.3×.

On the days it had one over the last 8 years, its median was 30.9×, from 9.4× in Jan 2023 to 485× in Dec 2020.

Price to free cash flow over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	22.3×	14.3×	24.1×
2025	17.2×	11.5×	17.8×
2024	n/m a value too high to mean anything
2023	77.7×	9.4×	81.0×
2022	10.4×	10.3×	118×
2021	n/m a value too high to mean anything
2020	485×	98.9×	485×
2019	133×	61.0×	164×
2018	208×	208×	369×

Against its peers

Companies in Healthcare nearest Champions Oncology's size, closest first, today.

Company	Price to free cash flow
CSBRChampions Oncology	n/m
SPROSpero Therapeutics	n/m
LFVNLifevantage	11.0×
APTAlpha Pro Tech	9.7×
ATNMActinium Pharmaceuticals	n/m
ICCCImmucell	22.1×
KEQUKewaunee Scientific	8.7×
NEPHNephros	n/m
PDEXPro DEX	29.5×
PLXProtalix BioTherapeutics	26.8×
NATRNatures Sunshine Products	11.8×
Peer median	11.8×

What the price to free cash flow tells you

Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.

Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.

More on Champions Oncology

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.